Immortalization of Human Lymphocytes by Fusion with Cytoplasts of Transformed Mouse L Cells

Hinrich Abken,* Herbert Jungfer,* Winfried H. W. Albert,* and Klaus Willecke*

*Institut für Zellbiologie (Tumorforschung), Universität (GHS) Essen, D-4300 Essen 1, Federal Republic of Germany; and

Boehringer Mannheim GmbH, Research Center, D-8132 Tutzing, Federal Republic of Germany.

Address all correspondence to H. Abken.

Abstract. Fusion of mouse L929 cytoplasts with human peripheral blood lymphocytes induced lymphocyte proliferation that gave rise to lymphoid cell lines of B and T cell origin with unlimited growth potential. The immortalized cell lines were routinely grown in standard medium supplemented with fetal calf serum. Furthermore these cell lines could be propagated in chemically defined serum-free media. Each establishment of lymphoid cell lines was preceded by a proliferation phase 2 wk after cytoplast/cell fusion, which appears to be a necessary step in the immortalization process.

The immortalized cells have a nearly normal human karyotype, do not form colonies in soft agar medium, and are not tumorigenic in nude mice. Cloned B cell lines produced human immunoglobulins of heavy and light chain types. No cross-reaction with DNA of herpes simplex virus, human cytomegalovirus, human T cell leukemia/lymphoma virus I and II, or polyoma virus was detected in the genome of immortalized cell lines by Southern blot hybridization. Furthermore B and T cell lines were established that appear to be free of Epstein-Barr virus genome.

The mechanisms by which normal somatic cells acquire unlimited proliferation potential are not fully understood. The conversion of mammalian cells with limited life span to permanent proliferation is considered to be an important step in the progression from normal to malignant phenotype. It has been suggested (24, 25) that certain oncogenes ("immortalizing genes") may separately or in combination influence cellular functions that drive the cell to divide autonomously or in response to self-secreted growth-promoting factors (autocrine growth control).

Normal human lymphocytes from peripheral blood are quiescent cells with limited life span in vitro that enter S-phase only if stimulated differently, resulting in clonal proliferation and maturation. Resting B cells can be activated to a proliferating stage by mitogens, by B cell growth factors, or via a pathway that requires T cell recognition of B cells and accessory cells. Upon recognition of their specific antigen, activated helper T cells release a variety of lymphokines and hemopoietic growth factors (30). Long term cultures of normal lymphocyte subpopulations have been established that are dependent for proliferation on appropriate growth factors, e.g., B cell growth factor (28) or anti-IgM (27) in the case of human B cells, and T cell growth factor (14) in the case of T cells. In the absence of appropriate antigens or growth factors, these lymphocyte populations undergo senescence.

The only known human B cell mitogen independent of accessory cells for its action is Epstein-Barr virus (EBV)1 which, after in vitro infection, immortalizes and transforms a subpopulation of human B lymphocytes. Only C3 receptor carrying B cells (33) can be infected by EBV. Like EBV, human T cell leukemia/lymphoma virus (HTLV) can transform normal lymphocytes in vitro to a stage of unlimited proliferation potential. Immortal T cell lines have been obtained by infection with both HTLV-I and HTLV-II (34, 44). Although B lymphocytes (5) and some nonlymphoid cells (6) can also be infected with HTLV, OKT4+ T cells appear to be the most permissive cells for viral replication and transformation. However, certain T cell lines remain T cell growth factor dependent upon HTLV infection.

In this paper, we describe a method for establishing human lymphoid cell lines of both B and T cell origin. Human lymphocytes were fused with isolated cytoplasts from mouse L929 cells. This procedure yielded lymphocyte populations 6-8 wk after fusion that can be routinely grown in standard medium or alternatively in chemically defined serum-free media without addition of hemopoietic growth factors. We isolated human B and T cell lines that appear to grow indefinitely without expressing the malignant phenotype.

Materials and Methods

Cells and Cell Lines

Mouse L929 cells were routinely grown in Dulbecco's modified Eagle's medium (DME) supplemented with 4 mM L-glutamine and 10% fetal calf serum. Mouse B and T cell lines were established that appear to grow indefinitely without expressing the malignant phenotype.

1. Abbreviations used in this paper: CMV, cytomegalovirus; DME, Dulbecco's modified Eagle's medium; EA, early antigen; EBNA, Epstein-Barr nuclear antigen; EBV, Epstein-Barr virus; HSA, human serum albumin; HSV, herpes simplex virus; HTLV, human T cell leukemia/lymphoma virus; PEG, polyethylene glycol; PWM, pokeweed mitogen; VCA, viral capsid antigen.

© The Rockefeller University Press, 0021-9525/86/09/795/11 $1.00
The Journal of Cell Biology, Volume 103, September 1986 795-805 795
serum. Mouse embryo fibroblasts were prepared from 12-d-old BALB/c mouse embryos. Briefly the embryos were dissected, incubated with collagenase (0.1 U/ml, Boehringer Mannheim GmbH, Mannheim, FRG) and dispase (0.8 U/ml, Boehringer Mannheim GmbH) in PBS for 1 h at 37°C, and washed twice in PBS. The cells were cultured in DME, supplemented with 4 mM l-glutamine, 1 mM pyruvate, 15 mM Hepes buffer, pH 7.2, and 20% fetal calf serum.

Lymphoid cell lines Raji (ATCC CCL 68), B95-8 (ATCC CRL 1612), and Mol-t-4 (ATCC CRL 1582) were grown in RPMI 1640 medium, 4 mM l-glutamine, and 10% fetal calf serum.

**Lymphocyte Isolation**

Peripheral blood was collected from healthy adults, heparinized, and diluted 1:2 in 3 mM citric acid, 100 mM dextrose, 70 mM NaCl, 30 mM sodium citrate, pH 6.1. The lymphocytes were separated according to Boyum (3) by centrifugation in a Metrizoat (Nyegaard Co., Oslo) gradient at 400 g for 30 min. After washing three times in PBS the lymphocytes were cultured in RPMI 1640 medium, 4 mM l-glutamine, 1 mM pyruvate, 1 mM oxalacetate, 0.1 U/ml insulin, 10 μg/ml transferrin, 15% fetal calf serum at 37°C in a humid atmosphere with 5% CO₂. For serum-free culture, lymphocytes were grown in Iscove's modified DME supplemented with SPM-2 (Boehringer Mannheim GmbH) or alternatively in HB 104 (New England Nuclear, Braunschweig, FRG). Both media were supplemented with human serum albumin (HSA; 0.5 μg/ml), pyruvate (1 mM), oxalacetate (1 mM), transferrin (0.1 U/ml), and Hepes (10 mM). B and T lymphocytes were separated by affinity chromatography using monoclonal anti-human-pan B cell or anti-human-pan T cell antibodies, respectively, covalently coupled to Sepharose. Briefly, mouse monoclonal anti-pan B cell or pan T cell antibodies (Miles, Bayar AG, FRG) were dissolved in 0.1 M NaHCO₃, 0.5 M NaCl, pH 8.5, and incubated with CNBr-activated Sepharose 6MB (Pharmacia Inc., Piscataway, NJ) (1 mg antibody/ml swollen gel) overnight at 4°C using an end-over-end mixer. To remove unbound antibodies the gel was washed three times for 30 min in 0.1 M NaHCO₃, 0.5 M NaCl, pH 8.5, and three times for 30 min in 0.1 M sodium acetate, 0.5 M NaCl, pH 4.5. To block the residual reactive groups the gel was incubated with 0.2 M glucosamine, 0.1 M sodium citrate, 0.5 M NaCl, pH 4.5, for 2 h at room temperature. Finally the gel was washed twice with PBS containing HSA (0.2%). For preparation of B cells, 10% peripheral blood lymphocytes, washed in PBS containing 0.2% HSA, were applied onto a column of anti-human-pan B cell antibodies coupled to Sepharose (5 ml). Before elution the column was incubated for 15 min at room temperature. The nonadherent cell fraction was eluted with 50 ml PBS, 0.2% HSA (flow rate 2 ml/min). To recover the absorbed cells, the column was incubated with 2 ml PBS, 0.2% HSA, 10 mg/ml IgG at 37°C without flow for 20 min, and mixed end-over-end. The cell fraction was eluted with PBS, 0.2% HSA, 10 mg/ml IgG. The contamination of non-B cells was <2% as estimated by indirect immunofluorescence using anti-human-pan B cell antibodies. The cell viability was >90% as determined by trypan blue exclusion test. Using anti-human-pan T cell antibodies coupled to Sepharose the T cell fraction could be separated as described for B cells.

**Preparation of L929 Cytoplasts**

Exponentially growing L929 cells were trypsinized and washed twice in serum-free DME. For induction of cytoplast formation, L929 cells (10⁶ cells/ml) were incubated in serum-free DME containing 50 μg/ml cytochalasin B at 37°C (1). Within 90 s blebs appeared on the cell surface. Before the blebs could aggregate at one pole of the cell surface, they were separated from the cells by vigorous vortexing for 40 s. After the cells were sedimented at 100 g for 10 min, the supernatant was centrifuged at 1,200 g for 15 min. The cytoplast pellet was resuspended in Ficoll (12.5%, Pharmacia Inc.) in serum-free DME and separated from nucleated cells according to Wigler and Weinstein (42) using a gradient with 2 ml 25% Ficoll, 2 ml 17% Ficoll, 0.5 ml 16% Ficoll, 0.5 ml 15% Ficoll, 2 ml 12.5% Ficoll in serum-free DME (from bottom to top). The suspension of cytoplasts was layered on top of the gradient and centrifuged at 100,000 g for 60 min at 30°C. The L929 cytoplasts were collected in the visible band at the 15-17% Ficoll region and washed twice in DME at 1,200 g for 15 min. Less than one nucleated cell per 1,000 cytoplasts was seen by fluorescence microscopy after staining with Hoechst 33,258. To prevent proliferation of contaminating L929 cells, the cytoplast fraction was treated with mitomycin C (400 μg/ml) for 15 min at 37°C.

**Immortalization Procedure**

To induce lymphocyte proliferation freshly prepared L929 cytoplasts (10⁶/0.5 ml serum-free DME) were added to 10⁵ human lymphocytes in 0.5 ml serum-free RPMI 1640. The cell/cytoplast suspension was incubated at 37°C for 15 min and sedimented for 20 s in an Eppendorf centrifuge. The sediment was resuspended in 1 ml 50% polyethylene glycol (PEG, 4,000 mol wt; SERVA Feinbiochemica GmbH & Co., Heidelberg, FRG), 150 mM Hepes, pH 7.5, prewarmed to 37°C. After 90±5 min serum-free RPMI 1640 medium was slowly added over a period of 5 min. The cell/cytoplast suspension was washed twice in RPMI 1640, and 2.5×10⁶ cells were seeded in 0.5 ml RPMI 1640, 4 ml l-glutamine, 1 mM pyruvate, 1 mM oxalacetic acid, 0.1 U/ml insulin, 10 μg/ml transferrin, 15% fetal calf serum per well of a 24-well microtiter plate. For the next 2 wk 50 μl of the medium in each well was changed every 2 d. During the following weeks 250 μl of the culture medium was replaced by fresh medium twice a week. The culture was first split 5 wk after fusion.

To estimate the extent of cell-to-cytoplast fusion, an aliquot of L929 cytoplasts (10⁶) was stained with Rhodamine 3B (10 μg/ml) (21) in serum-free RPMI 1640 for 30 min at room temperature. The lymphocyte nuclei were stained with Hoechst 33,258 (30 μg/ml serum-free RPMI 1640) for 10 min at 37°C. After cell/cytoplast fusion only cybrids carry a fluorescent nucleus surrounded by a Rhodamine 3B stained cytoplasm. The ratio of cybrids to nonfused cells was estimated by fluorescence microscopy.

**Cell Cloning**

Cell cloning was performed with a Cytofluorograf 50H interfaced with a model 2151 computer system (Ortho Diagnostic Systems Inc., Johnson & Johnson, Raritan, NJ) and equipped with an argon ion laser emitting 200 mW at 488 nm. Forward light scatter and 90° scatter were used to discriminate viable from nonviable cells. The flow rate was ~300 cells per second. The settings for sorting were deflection of one droplet per selected cell with rejection of coincidence over a span of three droplets. Cloning was done directly into 96-well culture plates by seeding a single cell per well containing 0.1 ml of lymphocyte culture medium.

The cloning efficiency in semi-solid agar medium was determined as described by MacPherson and Montaguer (26) using a 0.5% seaplaque agarose (Gibco, Grand Island, NY) base layer and a 0.32% seaplaque agarose layer in lymphocyte growth medium. After 3 wk colonies were counted under a Leitz stereo microscope.

**Tumorigenicity**

3-d-old NIH Swiss nu/nu mice were subcutaneously inoculated with 10⁴-10⁵ cells (in 100–500 μl PBS) from exponentially growing cell cultures. Any tumors obtained were explanted and the cells were grown in vitro to verify the tumorigenic cell type. An autopsy was performed after 5 mo when no tumor could be detected from outside.

**Immunoglobulin Assay**

Culture supernatants were analyzed for human immunoglobulins (Ig) by enzyme-linked immunosorbent assay (ELISA). Immunosorbent purified sheep antibodies to human IgM, IgA, or IgG (Boehringer Mannheim GmbH) and mouse monoclonal antibodies to human kappa- or lambda-chains (Seward Laboratory, Bedford, UK) were incubated in 96-well plates for 2 h at room temperature. The plates were coated with 1% BSA for 15 min, washed three times with PBS, and incubated with culture supernatants for 1 h. Then the plates were washed three times, incubated with peroxidase-conjugated sheep anti-human Ig (Boehringer Mannheim GmbH), for 2 h, washed four times, and 2,2' azino-di-(3-ethylbenzthiazolinsulfonate) (6) (Boehringer Mannheim GmbH) as substrate was added. Color changes were quantitated at 30 min using an automatic ELISA reader (SLT-Labinstruments, Salzburg). IgM production was measured with serial dilutions of culture supernatant using purified human myeloma IgM (Behringwerke, Marburg, FRG) as standard.

**Immunofluorescence**

Human B and T lymphocytes were detected by indirect immunofluorescence using a mouse monoclonal anti-human-pan B cell or pan T cell antibody, respectively (Miles). Washed lymphocytes (10⁶ cells) were incubated with 400 μl anti-human-pan B cell or pan T cell antibody (1:100 diluted in serum-
Immortalization of Human Lymphocytes

Abken et al.

human lymphocytes from the peripheral blood of healthy adults were mitogenically stimulated by incubation with pokeweed mitogen (PWM) 1 d after isolation. After 3–6 d [3H]thymidine incorporation reached the first maximum, which is called proliferation phase I (Fig. 1). Nonstimulated lymphocytes remain quiescent in vitro as shown by [3H]thymidine incorporation using parallel cultures supplemented with 20% autologous serum as control. At day 5 PWM-stimulated and nonstimulated, quiescent lymphocytes (10^7 cells each) were fused with cytoplasts from L929 cells (10^7 cytoplasts each) by incubation with PEG. Treatment with PEG without addition of L929 cytoplasts served as control. In addition the same number of quiescent and PWM-stimulated lymphocytes were co-cultivated with 10^7 L929 cytoplasts without PEG-mediated cytoplast/cell fusion. In all cases the induction of lymphocyte proliferation was monitored by [3H]thymidine incorporation assay (Fig. 1) and phase-contrast microscopy (Fig. 2). 3 d after cytoplast/cell fusion, clusters of lymphoid cells were observed. During the next 5 d these clusters rapidly increased in size and cell number to ~300–500 cells per colony. This we call proliferation phase II. Proliferating colonies were initially mostly adherent; at later times large colonies detached and gave rise to small colonies that grew in suspension. Up to 2 d after addition of L929 cytoplasts, cell proliferation ceased and [3H]thymidine incorporation decreased possibly due to cytotoxic effects of the cytoplast fraction. In the maximum of proliferation phase II, nonstimulated lymphocytes incorporated sixfold more [3H]thymidine upon PWM-mediated fusion with L929 cytoplasts, twofold more upon co-cultivation with L929 cytoplasts compared with control cultures which had not been treated with L929 cytoplasts. PWM-stimulated lymphocytes increased [3H]thymidine incorporation 100-fold upon PWM-mediated cytoplast/cell fusion and 50-fold upon co-cultivation with L929 cytoplasts. At this time no lymphocyte proliferation could be detected any more in parallel cultures not incubated with L929 cytoplasts.

Colonies proliferating in phase II required their own con-
ditioned medium. At the end of this proliferation phase, however, i.e., 17–24 d after cytoplast/cell fusion, the colonies grew in fresh culture medium provided that they were seeded at high cell densities (10^5 cells/ml). After three to five passages the cells could be diluted to 10^3 cells/ml and could be grown in serum-free media without addition of hemopoietic growth factors. Probably these cells had begun to produce their own growth factors which might have provided an autologous stimulus for self-renewal.

Proliferation phase II and subsequent infinite cell growth was only observed in lymphocyte populations treated with L929 cytoplasts. The resulting cell lines have been routinely grown in vitro for 1 yr (180 cell doublings) without any detection of growth arrest or senescence. Therefore we presume that these cell lines are immortalized. The maximum of [^3]H]thymidine incorporation during proliferation phase II and the frequency of immortalization was dependent on the extent of hybrid formation between L929 cytoplasts and lymphocytes (Table I). The rare induction of lymphocyte proliferation upon co-cultivation with L929 cytoplasts was possibly due to spontaneous cytoplast/cell fusions as monitored by fluorescence microscopy using Rhodamine 3B stained cytoplasts and Hoechst 33 258 stained lymphocytes as described in Materials and Methods.

In a second experiment we asked whether or not the L929 cytoplasts were mitogenic towards B or T lymphocytes and whether L929 cytoplasts could immortalize B or T lymphocytes. To analyze whether lymphocyte colonies in proliferation phase II were of B or T cell origin, parallel cultures were labeled with [^3]H]thymidine for autoradiography. The same cells were stained with monoclonal anti-human-pan B cell or pan T cell antibodies, respectively, for investigation of indirect immunofluorescence. 60% of all radioactively labeled colonies were of T cell origin, and 40% were of B cell origin (Table II). Colonies were either of B cell or T cell origin, suggesting that they were derived from single cells. 5–8 wk after cytoplast/cell fusion, rapidly proliferating lymphocyte cultures (cell doubling times 25–40 h) were 30–50% of B cell and 30–70% of T cell origin. B and T cell populations were cloned via dilution to single cells.

To measure the mitogenic activity of the cytoplast fraction towards purified B cell and T cell populations, the PWM-stimulated lymphocyte population was preparatively separated at day 6 by cell affinity chromatography on anti-human-pan B cell or pan T cell antibodies, respectively, coupled to Sepharose. Each cell fraction was fused or co-cultivated with L929 cytoplasts (10^7 cytoplasts per 10^7 lymphocytes). 7 d after addition of cytoplasts [^3]H]thymidine incorporation increased 400-fold in PWM-stimulated B cells upon PEG-mediated cytoplast/cell fusion and 300-fold upon cytoplast/cell co-cultivation compared with mock-treated PWM-stimulated B cell cultures. In contrast, PWM-stimulated T cells increased [^3]H]thymidine incorporation only sevenfold in the maximum 5 d after cytoplast/cell fusion or co-cultivation (Fig. 3). The results show that the L929 cytoplast fraction is up to 20-fold more mitogenic towards B cells than towards T cells but gives rise to both B cell and T cell lines that grow independently from exogeneous purified growth factors in serum-free media.

Now we asked whether or not immortalization could also be induced by fusion with cytoplasts from primary mouse fibroblasts of limited life span. Therefore cytoplasts from BALB/c mouse embryo fibroblasts in logarithmic growth phase (passage 3) were obtained by incubation with cytochalasin B, purified, and fused with quiescent or PWM-stimulated human lymphocytes at day 5 after lymphocyte isolation. During the following weeks no induction of lymphocyte proliferation could be detected by microscopic observation or [^3]H]thymidine incorporation assay, suggesting that the immortalization activity is restricted to cytoplasts from cell lines with unlimited proliferation potential.

Transmission electron micrographs of L929 cells used for enucleation showed that these cells possessed the usual fine structure features that characterize mammalian cells in culture. Studies on L929 cytoplasts used for immortalization revealed a normal cytoplasm with one to three mitochondria per cytoplast, parts of the Golgi apparatus and the endoplasmic reticulum, and numerous ribosomes. Cells of the immortalized lines of B and T cell origin showed fine structures indistinguishable from normal lymphocytes in vitro (Fig. 4).
Figure 2. Immortalization of lymphocytes by L929 cytoplast fusion as observed by phase-contrast microscopy. Primary lymphocytes (a) were stimulated with PWM and gave rise to proliferation phase I (b, day 4). Upon fusion with L929 cytoplasts at day 6 rapidly growing lymphocyte colonies were observed (proliferation phase II) (c at day 8; d at day 12; e at day 14). 8 wk after fusion immortalized lymphoid cell lines were established (f).

Table 1. Dependence of [H]Thymidine Incorporation during Proliferation Phase II and the Frequency of Immortalization Events on the Extent of Cybrid Formation between L929 Cytoplasts and Lymphocytes

| No. of lymphocytes | No. of L929 cytoplasts added | Cybrids | [H]Thymidine incorporation at maximum of proliferative phase II | Immortalized lymphoid cell clones |
|--------------------|-------------------------------|---------|---------------------------------------------------------------|---------------------------------|
| \(10^6\)           | \(10^7\)                      | \(35.2\) | \(230,500\)                                                  | 14                              |
| \(10^6\)           | \(10^6\)                      | \(32.7\) | \(210,000\)                                                  | 12                              |
| \(10^6\)           | \(10^5\)                      | \(2.43\) | \(151,000\)                                                  | 5                               |
| \(10^6\)           | \(10^4\)                      | \(0.17\) | \(10,200\)                                                   | 1                               |
| \(10^6\)           | \(10^3\)                      | \(0.07\) | \(5,700\)                                                    | 1                               |
| \(10^6\)           | \(10^2\)                      | \(0.01\) | \(500\)                                                      | 0                               |
| \(10^6\)           | 0                             | \(<0.01\) | \(200\)                                                       | 0                              |
Table II. Distribution of B and T Cells in Primary Lymphocyte Populations, during Proliferation Phase II, and in Immortalized Cell Lines 10 wk after Fusion with L929 Cytoplasts

| Cell type          | Primary lymphocytes | Proliferation phase II | Immortalized cell lines |
|--------------------|---------------------|------------------------|-------------------------|
|                    | B       | T       | B       | T       | B       | T       |
| Exp. 1             | 46      | 51      | 42      | 55      | 52      | 47      |
| Exp. 2             | 35      | 64      | 35      | 62      | 33      | 65      |
| Exp. 3             | 38      | 61      | 28      | 69      | 25      | 71      |
| Exp. 4             | 31      | 66      | 40      | 57      | 68      | 30      |

The cell diameter varied between 80 and 140 μm. The nucleus with fine granular chromatin contained two to three prominent nuclei and the cytoplasm carried numerous ribosomes as well as a large endoplasmatic reticulum, indicating active protein synthesis of the cells. The immortalized cell lines exhibited morphological diversity ranging from adherent cells to free floating round cells.

To derive monoclonal B and T cell lines, lymphocytes were fused with L929 cytoplasts and cloned by limiting dilution, or preferentially by single cell sorting. In a representative experiment lymphoid cells had a cloning efficiency of 23% (224 clones/960 cells seeded) using single cell sorting at day 41 after cytoplast fusion. As tested by ELISA 41.5% of the clones produced detectable amounts of Ig: IgM-lambda (27.2%), IgM-kappa (12.9%), IgG-kappa (0.9%), and lambda-chains only (0.4%). Out of 10 of the Ig-negative clones four expressed pan T cell marker, one expressed pan B cell marker, and five clones could not be classified by immunofluorescence using antibodies to human B and T cell marker.

To estimate the stability of Ig secretion one IgM-kappa and two IgM-lambda producing clones were reexamined after a 4-mo period of continuous growth. The clones tested produced IgM at similar quantities as at the first screening.

Five monoclonal cell lines were subjected to karyotype analysis. All lines had a modal number of human chromosomes of 46 (range 36–50). No mouse chromosomes were detectable by mouse centromere staining.

Five B cell lines and nine T cell lines were subjected to

Figure 3. Induction of B and T lymphocyte proliferation by L929 cytoplast fusion monitored by [3H]-thymidine incorporation assay. Lymphocytes were prepared at day 0 (○), stimulated with PWM at day 1 (●), and (a) co-cultivated (○) or fused (●) with L929 cytoplasts at day 6 (arrow). A parallel culture of lymphocytes (b) was fractionated in B and T cells. The cell fractions were co-cultivated (B cells, ●; T cells, △) or fused (B cells, ○; T cells, △) with L929 cytoplasts.
Figure 4. Transmission electron micrographs of a primary lymphocyte (day 3 in vitro) (a), lymphocytes incubated with L929 cytoplasts at day 6 (b), and mononuclear cells of immortalized cell lines (c and d) 12 wk after fusion with L929 cytoplasts.

cytometric DNA measurement. Their histograms revealed a DNA content similar to that of nontransformed human blood lymphocytes.

To characterize the transformed phenotype of the immortalized lymphoid cell lines the cloning efficiency in soft agar medium and the tumorigenicity in NIH Swiss nu/nu mice upon subcutaneous injection were tested. As shown in Table III, cells of the immortalized lines of B cell or T cell origin did not form colonies in soft agar medium (frequency \(\leq 10^{-5}\)) like quiescent lymphocytes. In contrast the malignantly transformed human Burkitt lymphoma line Raji and the T cell leukemia line Molt-4 exhibited cloning efficiencies of 10.8% and 9.8%, respectively. Upon subcutaneous injection in 3-d-old NIH Swiss nu/nu mice, cells of the immortalized lymphoid lines of B or T cell origin \((10^4-10^7\) cells per mouse\) did not induce tumors at the injection site nor could tumors be detected at autopsy 5 mo after injection (Table III). When equal numbers of primary human lymphocytes were
blast cells that can be easily established in vitro as infinitely
munofluorescence. EA and VCA were assayed by indirect

cules integrated into the chromosomal DNA (16). In the
as multiple unintegrated molecules as well as linear mole-
could be detected in the cytoplasm. The EBV DNA is present
the EBNA was found to be expressed (36) and in produc-

mortalization process of human lymphocytes by fusion with

EBV transforms human lymphocytes into proliferating
blast cells that can be easily established in vitro as infinitely
proliferating cell lines. In nearly all cells infected by EBV,
the EBNA was found to be expressed (36) and in produc-
tively infected cells the Epstein-Barr EA (18) and VCA (17)
could be detected in the cytoplasm. The EBV DNA is present
as multiple unintegrated molecules as well as linear mole-
cules integrated into the chromosomal DNA (16). In the
lymphoid cell lines immortalized by L929 cytoplast fusion,
expression of EBNA was tested by anti-complement im-

purified B and T cell colonies during proliferation phase II
or in immortalized EBNA-negative B cell clones or in T cell
clones (Fig. 5). This suggested that the EBV genome is un-
likely to be involved in the immortalization of B and T cell
clones by fusion with L929 cytoplasts.

Since HSV replicates upon infection in both mitogen-
stimulated B and T lymphocytes and in myeloid cell lines
(22), we checked whether the HSV genome was present in
the DNA of human lymphocytes. The HSV-2 Bgl II N-frag-
mament is known to establish transformed rodent fibroblast
lines upon DNA transfection (11). Therefore we probed by
Southern blot hybridization total cellular DNA isolated from
L929 cells, primary human lymphocytes, B and T cell colo-

Human CMV causes latent, nonproductive infections in
lymphoid cells (41) harboring the CMV genome (20). Trans-
factions of rodent cells with overlapping cloned fragments of
the CMV genome (strain AD 169) identified a transforming
490-bp fragment near the right end of the genome (32). By
Southern blot hybridization with the cloned probe of the
transforming region (pCM 5018) (31) we could not detect any
hybridization with the cellular DNA of the immortalized
lymphoid cell lines of B cell or T cell origin or with DNA
from L929 cells, lymphocytes in proliferation phase II upon
fusion with L929 cytoplasts or primary lymphocytes. Plas-
mid DNA (4 pg, equivalent to about one copy/cell) served as positive control.
Abken et al.  *Immortalization of Human Lymphocytes*  803

**Figure 5.** Southern blot hybridization of EBV internal repeat sequence with DNA of lymphoid cells. Cellular DNA (15 μg) was digested with Bam HI, separated in a 0.8% agarose gel, transferred to a nitrocellulose filter, and hybridized with the cloned 3.1-kbp Bam HI-fragment W of the cloned 3.1-kbp Bam HI-fragment W of EBV internal repeat sequence (15) isolated from pBR 322 DNA before nick-translation (10⁶ cpm/μg DNA). Lane a, DNA of lymphocytes from peripheral blood; lane b, B lymphocyte clone during proliferation phase I; lane c, T lymphocyte clone during proliferation phase II; lanes d and e, immortalized, EBNA-negative B lymphoid cell clones; lanes f and g, immortalized, EBNA-negative T lymphoid cell clones; lane h, L929 cells; lane i, pEB-W DNA, digested with Bam HI (cloned EBV internal repeat sequence, Bam HI-fragment W) (6 pg; equivalent to about 1 EBV internal repeat copy/cell or to about 0.1 EBV genome equivalent/cell). Eco RI/Hind III fragments of λ DNA served as molecular weight standard.

HTLV, types I and II, transform normal human lymphocytes to infinite proliferation upon infection in vitro (29, 37). Although OKT4+ T cells appear to be the most permissive cells, certain B lymphocytes (5) and nonlymphoid cells (6) can also be infected by HTLV. In the genome of the lymphoid cells immortalized by L929 cytoplast fusion, we could not detect the HTLV-I or HTLV-II genome by Southern blot hybridization using the cloned 8.3-kbp SstI-proviral fragment (pMT-2; HTLV-I) (37) and the 3.5-kbp Bam HI-proviral fragment (pMO1A; HTLV-II) (13), respectively, as probe. Plasmid DNA (24 pg and 14 pg, respectively, equivalent to about one copy/cell) served as positive control.

In addition we could not detect hybridization to the polyoma virus genome in DNA of the immortalized cell lines using the cloned complete polyoma virus genome (pPB21) (12) as probe.

These results suggest that EBV, HSV types 1 and 2, human CMV, HTLV I and II, and polyoma virus may not be involved in the process of immortalization by fusion with L929 cytoplasts.

Mouse cells are known to harbor endogeneous retroviruses and to produce retroviruses under certain conditions. To check if the lymphoid cell lines immortalized by fusion with L929 cytoplasts produce retroviruses, we tested the activity of reverse transcriptase in the culture supernatant of these cell lines. No reverse transcriptase activity could be detected in the supernatant of the immortalized human cell lines tested, showing that no retroviruses were produced by these cells.

**Discussion**

In this paper we describe the induction of human lymphocyte proliferation by fusion with cytoplasts from mouse L929 cells generating permanently growing lymphoid cell populations of both B and T cell origin. These cell lines can be routinely grown in vitro in serum-supplemented media and in chemically defined serum-free media without addition of hemopoietic growth factors, suggesting that these cells possibly secrete their own growth factors. The cell lines have been maintained in culture for 1 yr (>180 cell doublings) without any detection of growth arrest or senescence. We presume that these cell lines are immortalized since quiescent or lectin-stimulated human control lymphocytes undergo senescence at day 3 or at day 10 in vitro, respectively, and human fibroblasts achieve ~50 cell doublings in culture. While the cell doubling time of 25-40 h is similar to other malignant lymphoid cell lines, these immortalized cells do not form colonies in soft agar medium (frequency <10⁻⁵) and do not induce tumors upon subcutaneous injection of up to 10⁷ cells in nude mice.

Stable human B cell and T cell lines could be established by fusion with L929 cytoplasts and could be cloned by single cell cloning. These clones contained a nearly diploid set of human chromosomes. Murine chromosomes were regularly absent as revealed by centromere staining. Neither a systematical loss of duplication of single human chromosomes, nor systematical rearrangements could be recorded.

Cloned B cell lines produced human Ig with monoclonally restricted heavy chain classes and light chain types. Over a period of 4 mo B cell clones secreted continuously Ig in microgram quantities per 10⁶ cells. These results suggest that the immortalization method described will be useful in the generation of monoclonal human antibodies with pre-defined specificity.

Earlier attempts to generate immortalized human immunoglobulin-producing cells involved the fusion of human lymphoid cells with mouse myeloma cells (4). The interspecies hybridomas tended to cease human immunoglobulin production due to the selective loss of human chromosomes (9) or to disturbances of gene expression (35). However, interspecies hybridomas generated by fusion of antigen-primed human B lymphocytes with EBV-transformed B lymphoblastoid cell lines (40) secrete immunoglobulin molecules derived from both fusion partners (23), and the amount of immunoglobulin secreted can vary 100-fold among several clones (7). Our results show that human B lymphocytes immortalized by L929 cytoplast fusion give rise to cell lines that stably produce human homogeneous antibodies and do not express the malignant phenotype.

Cytoplasts derived from transformed mouse L929 cells transfer an immortalizing activity on quiescent or lectin-prestimulated human B and T lymphocytes in contrast to cytoplasts from primary mouse embryo fibroblasts with limited life span. This suggests that the immortalization ac-
Proliferation phase is a necessary step in the immortalization phase. Some of the competent cells fused with L929 cells to form continuous lymphocyte proliferation. During the proliferation phase, human lymphocytes are present, and cytoplast/cell contact or PEG-mediated fusion of B cell and T cell antibodies is used.

Lymphoid cell lines are lymphoid in origin since they grow in suspension, near the diploid human karyotype. (b) The immortalized cell lines are derived from whole somatic cells. We only observed lymphocyte immortalization after some cell doublings. Normal diploid cells may divide but do not grow in suspension. (c) Alternatively genetic material of such a factor may instead result in transient cell activation.

Due to our results described above, we think it unlikely that the immortalized cell lines were derived from whole somatic cell hybrids: (a) All lymphoid cell lines tested have a proliferation potential. At this time, many cells of finite life span will continue to divide slowly. After more than 6 wk, the fused cell population is homogeneous and clonogenic and steadily proliferative. Our observations based on light microscopy and ³H-thymidine incorporation suggest that the proliferation phase II does not directly lead to immortalization but is followed by a crisis of proliferation. At least three hypothetical mechanisms can be envisaged to explain the results: (a) A minimum number of proliferation initiations transferred by a trans-acting cytoplasmic factor of L929 cytoplasts is needed for establishment of a lymphoid lineage. During the critical period of proliferation, this factor(s) must achieve a level sufficient for immortalization, and suboptimal concentrations of such a factor may instead result in transient cell activation. (b) Alternatively initiation of proliferation may occur very frequently followed by reversions to normal senescent cells after some cell doublings. Normal diploid cells may synthesize an inhibitor that blocks the initiation of DNA synthesis at the time the cell has completed its in vitro life span (38). During proliferation, the synthesis of the inhibitor may be repressed. L929 cytoplasts could harbor a factor that maintains the repression of inhibitor genes of DNA synthesis or that alters the expression of inhibitor gene(s) or functionally neutralizes the inhibitor gene products in indefinitely proliferating lymphocytes. (c) Alternatively genetic material may be transferred by cytoplast fusion from L929 cells into human lymphocytes. The genome of several mouse endogenous DNA or RNA viruses may induce lymphocyte proliferation and give rise to continuously growing cell lines. Due to our results described above, we think it unlikely that the genome of EBV, HSV types 1 and 2, human CMV, HTLV I and II, or polyoma virus is transmitted to or induced in the recipient cells by L929 cytoplasts. These viruses are probably not involved in the induction of lymphocyte immortalization. In addition, no activity of reverse transcriptase could be detected in the culture supernatant indicating that no retroviruses are produced by the immortalized cell lines.

Although the immortalizing agent transferred by L929 cytoplasts is unknown yet, L929 cytoplast fusions may be used to generate a panel of nontumorigenic human lymphoid cell lines of B and T cell origin for studies of lymphocyte heterogeneity and function.

We thank H. Barchet for his valuable contributions during the initial phase of this work. B. Goller for cell sorting and cytofluorography, and M. Chlupka and E. N. Schmid for electron microscopy. We also thank Drs. G. Bornkamm, Freiburg, FRG, L. Bouchard, Toronto, Canada, and H. Wolf, Munich, FRG, for the recombinant plasmids pCM 5018 (CMV), pEBdimerW (EBV), pHBL0 (HSV), pMT-2 (HTLV-I), pMOHA (HTLV-II), and pBP21 (polyoma virus).

H. Abken and K. Willecke acknowledge the financial support of the Boehringer Mannheim GmbH for this research project.

Received for publication 27 March 1986, and in revised form 6 May 1986.

References

1. Allikmets, E., I. Vasil'ev, and I. Rovenkii. 1983. Effect of cytochalasins on the surface topography of neoplastic cells in suspension. Bull. Exp. Biol. Med. (Engl. Transl. Byull. Eksp. Biol. Med.). 95:84–87.

2. Brentdii, M., J. Doehmer, K. Willecke, J. Doehsman, and R. Jaenisch. 1983. Mouse line integration of Moloney leukemia virus: identification of the chromosomal integration site. Proc. Natl. Acad. Sci. USA. 76:1938–1942.

3. Béygue, A. 1968. A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. Scand. J. Clin. Lab. Invest. 21(Suppl. 97): 51–76.

4. Butler, J. L., H. C. Lane, and A. S. Fauci. 1983. Delineation of optimal conditions for producing mouse-human heterohybridomas from human peripheral blood B-cells of immunized subjects. J. Immunol. 130:165–168.

5. Chen, I., S. G. Quan, and D. W. Golde. 1983. Human T-cell leukemia virus type II transforms normal human lymphocytes. Proc. Natl. Acad. Sci. USA. 80:7006–7009.

6. Clapham, P., K. Nagy, R. Cheingang-Poppov, M. Esley, and R. A. Weiss. 1983. Productive infection and cell-free transmission of human T-cell leukemia virus type II in a non-lymphoid cell line. Science (Wash. DC). 222:1125–1127.

7. Cote, R. J., D. M. Morrissey, A. N. Houghton, E. J. Beatie, H. F. Oettgen, and L. J. Old. 1983. Generation of human monoclonal antibodies reactive with cellular antigens. Proc. Natl. Acad. Sci. USA. 80:2026–2030.

8. Cissmann, H. A., P. F. Mullane, and J. A. Steinkamp. 1975. Methods and application of flow systems for analysis and sorting of mammalian cells. Methods Cell Biol. 9:179–246.

9. Croce, C. M., M. Shander, J. Martinis, L. Circurel, G. G. D'Ancona, and H. Koprowski. 1980. Preferential retention of human chromosome 14 in mouse X human B-cell hybrids. Eur. J. Immunol. 10:486–488.

10. Dan, H., R. Jaenisch, and P. Macleac. 1978. Lymphocyctic infection of Moloney murine leukemia virus in mouse cells: effect on number of viral DNA copies and virus production in producer cells. J. Virol. 28:802–809.

11. Gallows, D. A., J. A. Nelson, and J. K. McDougall. 1984. Small fragment of herpes virus DNA with transforming activity contains an initiation sequence-like structure. Proc. Natl. Acad. Sci. USA. 81:4736–4740.

12. Gellin, C., L. Bouchard, and M. Bastin. 1981. Tumorigenic activity of cloned polyoma virus DNA in newborn rats. Experientia. 37:1074–1077.

13. Geitman, E. J., G. Francini, V. Manzani, F. Wong-Staal, and R. C. Gallo. 1984. Molecular cloning of a unique human T-cell leukemia virus (HTLV-II Mo). Proc. Natl. Acad. Sci. USA. 81:993–997.

14. Gillis, S., M. M. Fern, W. Ou, and K. A. Smith. 1978. T-cell growth factor, parameters of production and a quantitative microassay for activity. J. Immunol. 120:2027–2032.

15. Hayward, S. D., L. Nogee, and G. S. Hayward. 1983. Generation of human monoclonal antibodies reactive with cellular antigens. Proc. Natl. Acad. Sci. USA. 80:2026–2030.

16. Henderson, A., S. Ripley, M. Heller, and E. Kieff. 1983. Chromosome site of Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes grown transformed in vivo. Proc. Natl. Acad. Sci. USA. 80:1987–1991.

17. Henle, G., and W. Henle. 1966. Immunofluorescence in cells derived from Burkitt's lymphoma. J. Bacteriol. 91:1248–1256.

18. Henle, W., G. Henle, B. A. Zajac, G. Pearson, R. Wabke, and M. Scriba. 1973. Differential reactivity of human sera with early antigens induced by Epstein-Barr virus. Science (Wash. DC). 169:188–190.

19. Hilweg, I., and A. Gropp. 1972. Staining of constitutive heterochromatin in mammalian chromosomes with a new fluorochrome. Exp. Cell Res. 75:122–126.

20. St. Jeor, S. C., and A. Weisser. 1977. Persistence of cytomegalovirus

The Journal of Cell Biology, Volume 103, 1986

804
in human lymphoblasts and peripheral leukocyte cultures. *Infect. Immunol.* 15:402–409.

21. Johnson, D. R., M. L. Walsh, and L. B. Chen. 1980. Localization of mitochondria in living cells with rhodamine 123. *Proc. Natl. Acad. Sci. USA.* 77:990–994.

22. Kleinman, L. F., S. Kibrick, F. Ennis, and P. Polgar. 1972. Herpes simplex virus replication in human lymphocyte cultures stimulated with phytohemagglutinin and anti-lymphocyte globulin. *Proc. Soc. Exp. Biol. Med.* 141:1095–1098.

23. Kozbor, D., A. E. Lagarde, and J. C. Roder. 1982. Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines. *Proc. Natl. Acad. Sci. USA.* 79:6651–6655.

24. Land, H., L. F. Parada, and R. A. Weinberg. 1983. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. *Nature (Lond.)* 304:596–602.

25. Land, H., L. F. Pamda, and R. A. Weinberg. 1983. Cellular oncogenes and multistep carcinogenesis. *Science (Wash. DC).* 222:771–778.

26. MacPherson, I., and L. Montagnier. 1964. Agar suspension culture for the selective assay of cells transformed by polyoma virus. *Virology.* 23:291–294.

27. Maizel, A., J. Morgan, S. Mehta, N. Kouttab, J. Bator, and D. Sahasrabuddhe. 1983. Long-term growth of human B-cells and their use in a microassay for B-cell growth factor. *Proc. Natl. Acad. Sci. USA.* 80:5047–5051.

28. Maizel, A., C. Sahasrabuddhe, S. Mehta, J. Morgan, L. Lachman, and R. Ford. 1982. Biochemical separation of a human B-cell mitogenic factor. *Proc. Natl. Acad. Sci. USA.* 79:5998–6002.

29. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. *Molecular Cloning.* Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 545 pp.

30. Marrack, P., S. D. Graham, E. Kushnir, H. J. Leibson, N. Roehm, and J. W. Kappler. 1982. Nonspecific factors in B-cell response. *Immunol. Rev.* 63:33–50.

31. Nelson, J. A., B. Fleckenstein, D. A. Galloway, and J. K. McDougall. 1982. Transformation of NIH 3T3 cells with cloned fragments of human cytomegalovirus strain AD 169. *J. Virol.* 43:83–91.

32. Nelson, J. A., B. Fleckenstein, G. Jahn, D. A. Galloway, and J. K. McDougall. 1984. Structure of the transforming region of human cytomegalovirus Ad 169. *J. Virol.* 49:109–115.

33. Nilsson, K., and G. Klein. 1982. Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance of the etiology of Burkitt's lymphoma. *Adv. Cancer Res.* 37:219–380.

34. Popovic, M., G. Lange-Wantzin, P. S. Sarin, D. Mann, and R. C. Gallo. 1983. Transformation of human umbilical cord blood T cells by human T-cell leukemia/lymphoma virus. *Proc. Natl. Acad. Sci. USA.* 80:5402–5406.

35. Raison, R. L., K. Z. Walker, C. R. E. Halman, D. Briscoe, and A. Basten. 1982. Loss of secretion in mouse-human hybrids need not be due to the loss of a structural gene. *J. Exp. Med.* 156:1380–1389.

36. Reedman, B. M., and G. Klein. 1973. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and nonproducer lymphoblastoid cell lines. *Int. J. Cancer.* 11:499–520.

37. Seki, M., S. Hattori, and M. Yoshida. 1982. Human adult T-cell leukemia virus: molecular cloning of the provirus DNA and the unique terminal structure. *Proc. Natl. Acad. Sci. USA.* 79:6898–6902.

38. Shall, S., and W. D. Stein. 1979. A nontemplation theory for the control of cell proliferation and for the origin of immortal cell lines. *J. Theor. Biol.* 76:219–231.

39. Southern, E. M. 1975. Detection of specific sequences among DNA fragments separated by gel electrophoresis. *J. Mol. Biol.* 98:503–517.

40. Steinlitz, M., and S. Tamir. 1982. Human monoclonal autoimmune antibody produced in vitro: rheumatoid factor generated by Epstein-Barr virus-transformed cell line. *Eur. J. Immunol.* 12:126–133.

41. Tocci, M. J., and S. C. St. Jeor. 1979. Susceptibility of lymphoblastoid cells to infection with human cytomegalovirus. *Infect. Immunol.* 23:418–428.

42. Wigler, M. M., and J. B. Weinstein. 1975. A preparative method for obtaining enucleated mammalian cells. *Biochem. Biophys. Res. Commun.* 63:669–674.

43. Worton, R. G., and C. Duff. 1979. Karyotyping. *Methods Enzymol.* 58:322–344.

44. Yamamoto, N., M. Okada, Y. Koyanagi, M. Kannagi, and Y. Hinuma. 1982. Transformation of human leukocytes by cocultivation with an adult T cell leukemia virus producer cell line. *Science (Wash. DC).* 217:737–739.